The proportion of Th22 cells (75, 76) and the level of IL-22 in the serum of patients with MS increased (75, 76, 115–121), and the level of IL-22 in recurrent stage was significantly higher than that in progressive stage and remission stage (115, 116, 119, 122). Here, IL22 is linked to myeloid sarcoma.